50 Participants Needed

Nivolumab for Cancer

Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: Mayo Clinic
Must be taking: Nivolumab
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial
Breakthrough TherapyThis drug has been fast-tracked for approval by the FDA given its high promise
Approved in 4 JurisdictionsThis treatment is already approved in other countries

Trial Summary

Do I need to stop my current medications for the trial?

The trial protocol does not specify if you need to stop taking your current medications. However, you cannot participate if you are receiving other investigational or standard treatments for your cancer that are not part of the eligible treatment regimen.

What data supports the effectiveness of the drug Nivolumab for cancer treatment?

Nivolumab has shown significant effectiveness in treating advanced non-small cell lung cancer (NSCLC), with better overall survival and response rates compared to traditional chemotherapy. It is also approved for use in several other cancers, including melanoma and renal cell cancer, indicating its broad potential in cancer treatment.12345

Is Nivolumab safe for humans?

Nivolumab, also known as Opdivo, is generally considered safe, but it can cause immune-related side effects, which are usually manageable but can be severe in some cases. These side effects may include inflammation of the colon (colitis) and blood-related issues, which are rare but potentially serious.678910

How is the drug Nivolumab unique in treating cancer?

Nivolumab is unique because it is a PD-1 immune checkpoint inhibitor that helps the immune system recognize and attack cancer cells, offering a new option for patients who have not responded to traditional chemotherapy. It is administered intravenously and has shown better survival rates and tolerability compared to some existing treatments like docetaxel, especially in advanced lung cancer and melanoma.1231112

What is the purpose of this trial?

This phase II trial compares the impact of subcutaneous (SC) nivolumab given in an in-home setting to an in-clinic setting on cancer care and quality of life. Currently, most drug-related cancer care is conducted in clinic type centers or hospitals which may isolate patients from family, friends and familiar surroundings for many hours per day. This separation adds to the physical, emotional, social, and financial burden for patients and their families. Traveling to and from medical facilities costs time, money, and effort and can be a disadvantage to patients living in rural areas, those with low incomes or poor access to transport. Studies have shown that cancer patients often feel more comfortable and secure being cared for in their own home environments. SC nivolumab in-home treatment may be safe, tolerable and/or effective when compared to in-clinic treatment and may reduce the burden of cancer and improve the quality of life in cancer patients.

Research Team

RS

Roxana S. Dronca, M.D.

Principal Investigator

Mayo Clinic

Eligibility Criteria

This trial is for patients with various cancers, including kidney, skin, lung, and others. It's designed for those who may benefit from receiving treatment at home due to difficulties traveling to medical facilities or a preference for the comfort of their own environment.

Inclusion Criteria

My cancer type is approved for nivolumab treatment by the FDA.
I am willing to switch to injections for my treatment.
I am moving to nivolumab alone after finishing treatment with both Ipilimumab and nivolumab.
See 15 more

Exclusion Criteria

I have not received any live vaccines in the last 30 days.
HIV positive with AIDS defining opportunistic infection within the last year or CD4 count < 350 cells/uL unless meeting specific criteria
History of allergy or hypersensitivity to study drug components
See 14 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

In-Clinic Treatment

Participants receive nivolumab SC in clinic for 2 cycles, each cycle lasting 28 days

8 weeks
2 visits (in-person)

In-Home Treatment

Participants receive nivolumab SC at home by a home health nursing provider for 4 cycles, each cycle lasting 28 days

16 weeks
4 visits (in-home)

Extended Treatment

Participants continue nivolumab SC administration either in-clinic or at-home for up to 1 year in the absence of disease progression or unacceptable toxicity

Up to 1 year

Follow-up

Participants are monitored for safety and effectiveness after treatment completion

Up to 1 year
Follow-up at days 30 and 100, then every 3 months

Treatment Details

Interventions

  • Nivolumab
Trial Overview The study compares subcutaneous Nivolumab administration at home versus in a clinic setting. The focus is on how this affects cancer care quality and patient quality of life. It's a phase II trial that explores whether home treatment can be as safe and effective as clinic-based care.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Health services research (in-clinic and at-home nivolumab)Experimental Treatment4 Interventions
Patients receive nivolumab SC on day 1 of each cycle. Cycles repeat every 28 days in clinic for 2 cycles, then at home by a HHNP for 4 cycles, followed by either in-clinic or at-home administration for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients receive in-home visits by a home health nurse and undergo remote patient monitoring including vital sign measurements and condition-specific symptom assessments throughout study.

Nivolumab is already approved in United States, European Union, Canada, Switzerland for the following indications:

🇺🇸
Approved in United States as Opdivo for:
  • Advanced or metastatic gastric cancer
  • Gastroesophageal junction cancer
  • Esophageal adenocarcinoma
  • Melanoma
  • Non-small cell lung cancer
  • Renal cell carcinoma
  • Hodgkin lymphoma
  • Head and neck squamous cell carcinoma
  • Urothelial carcinoma
  • Colorectal cancer
  • Hepatocellular carcinoma
  • Esophageal squamous cell carcinoma
🇪🇺
Approved in European Union as Opdivo for:
  • Melanoma
  • Non-small cell lung cancer
  • Renal cell carcinoma
  • Hodgkin lymphoma
  • Head and neck squamous cell carcinoma
  • Urothelial carcinoma
  • Colorectal cancer
  • Gastric cancer
  • Gastroesophageal junction cancer
  • Esophageal adenocarcinoma
🇨🇦
Approved in Canada as Opdivo for:
  • Melanoma
  • Non-small cell lung cancer
  • Renal cell carcinoma
  • Hodgkin lymphoma
  • Head and neck squamous cell carcinoma
  • Urothelial carcinoma
  • Colorectal cancer
  • Gastric cancer
  • Gastroesophageal junction cancer
  • Esophageal adenocarcinoma
🇨🇭
Approved in Switzerland as Opdivo for:
  • Melanoma
  • Non-small cell lung cancer
  • Renal cell carcinoma
  • Hodgkin lymphoma
  • Head and neck squamous cell carcinoma
  • Urothelial carcinoma
  • Colorectal cancer
  • Gastric cancer
  • Gastroesophageal junction cancer
  • Esophageal adenocarcinoma

Find a Clinic Near You

Who Is Running the Clinical Trial?

Mayo Clinic

Lead Sponsor

Trials
3,427
Recruited
3,221,000+

Findings from Research

Nivolumab, an anti-PD-1 antibody, was administered to a 63-year-old female patient with metastatic melanoma after renal transplantation, highlighting the potential for anti-tumor activity in high-risk patients, despite the challenges of concurrent immunosuppression.
The patient experienced acute renal allograft rejection and renal failure shortly after starting nivolumab, indicating significant risks associated with this treatment in transplant recipients, but she later showed a positive clinical response after re-challenging with nivolumab while on hemodialysis.
Antitumor activity of nivolumab on hemodialysis after renal allograft rejection.Ong, M., Ibrahim, AM., Bourassa-Blanchette, S., et al.[2023]
Nivolumab, an immune checkpoint inhibitor, significantly improved overall survival and progression-free survival compared to docetaxel in patients with advanced squamous non-small cell lung cancer (NSCLC) in the CheckMate 017 trial.
Nivolumab was better tolerated than docetaxel, with manageable adverse effects, making it a promising treatment option for patients who have already undergone chemotherapy.
Nivolumab: a review in advanced squamous non-small cell lung cancer.Keating, GM.[2022]
Nivolumab (Opdivo) significantly improves overall survival and response rates in previously-treated patients with advanced nonsquamous non-small cell lung cancer (NSCLC) compared to docetaxel, as shown in the CheckMate 057 trial.
Nivolumab has a manageable adverse event profile and is better tolerated than docetaxel, making it a valuable treatment option for patients who have progressed after chemotherapy.
Nivolumab: A Review in Advanced Nonsquamous Non-Small Cell Lung Cancer.Keating, GM.[2018]

References

Antitumor activity of nivolumab on hemodialysis after renal allograft rejection. [2023]
Nivolumab: a review in advanced squamous non-small cell lung cancer. [2022]
Nivolumab: A Review in Advanced Nonsquamous Non-Small Cell Lung Cancer. [2018]
The benefit and risk of nivolumab in non-small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized controlled trials. [2019]
Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable. [2022]
Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports. [2020]
Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event Data. [2022]
The risks of hematological toxicities of nivolumab in cancer patients: A PRISMA-compliant meta-analysis. [2023]
Analysis of Pleiotropic Effects of Nivolumab in Pretreated Advanced or Recurrent Non-small Cell Lung Cancer Cases. [2020]
Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma. [2019]
Nivolumab: a review of its use in patients with malignant melanoma. [2021]
Nivolumab in the treatment of metastatic squamous non-small cell lung cancer: a review of the evidence. [2018]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security